Enliven Therapeutics, Inc. (ELVN)

Over the past six months, Enliven Therapeutics' stock has experienced notable events. As of February 5, 2026, the stock price was $26.99. In January 2026, the stock saw a significant intraday surge and heavy trading volume following the announcement of positive initial Phase 1b data for ELVN-001 in chronic myeloid leukemia, leading to a 50.29% increase on January 8, 2026. The company also bolstered its board in January 2026 to prepare for its next phase of development. In December 2025, Enliven Therapeutics reported inducement grants. The stock has fluctuated between $13.30 and $29.98 over the past 52 weeks. Analysts have shown strong support for Enliven, with a consensus of "Moderate Buy" and an average target price of $41.00, suggesting a potential upside. Insider selling activity was observed in January 2026 from several co-founders and officers, while the CFO made a buy in December 2025.

As a clinical-stage biopharmaceutical company, Enliven Therapeutics, Inc. is focused on the discovery and development of therapeutic candidates and is not yet generating revenue from commercialized products. Therefore, there is no established demand seasonality for its products or services in the traditional sense. The company's financial performance and stock valuation are primarily driven by progress in its clinical trials, regulatory milestones, and investor sentiment regarding its pipeline.

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for cancer patients, operating within the biotechnology sector. The company's primary focus is on precision oncology, aiming to develop therapies that improve survival and enhance patient well-being. The company is advancing two main product candidates: ELVN-001, a kinase inhibitor in Phase 1 clinical trials for previously treated CML, and ELVN-002, a CNS penetrant HER2 inhibitor in Phase 1 clinical trials for NSCLC and other HER2-driven cancers and solid tumors.

Enliven Therapeutics, Inc. is headquartered in Boulder, Colorado, USA. While the company's operations are based in the United States, its institutional ownership shows a significant presence of US-based investors, with 82.0% of its shareholders originating from the US.

Enliven Therapeutics generally holds a positive brand reputation, particularly among analysts. The company has received a consensus rating of "Moderate Buy" from analysts, with nine buy ratings and no hold or sell recommendations reported in August 2025. The positive updated data from the ELVN-001 clinical trial in June 2025 also contributed positively to its reputation. There is no readily available information indicating specific events that have negatively impacted Enliven Therapeutics, Inc.'s reputation in the past year.

Enliven Therapeutics, Inc. has a substantial institutional ownership, with 246 institutional owners holding a total of 63,086,010 shares. Major institutional shareholders include Orbimed Advisors Llc, Fmr Llc, Commodore Capital Lp, Fairmount Funds Management LLC, BlackRock, Inc., VR Adviser, LLC, Polar Capital Holdings Plc, Vanguard Group Inc, Janus Henderson Group Plc, and Novo Holdings A/S. Institutional ownership accounts for approximately 89.05% to 100.19% of the company's shares. Individual investors hold about 3.76% of the shares. Insider ownership stands at 35.42% of outstanding equity as of January 10, 2026.